Abstracts tagged "quality of life"

Abstract Number: 1210 • ACR Convergence 2020
Patient-Reported Outcomes Measurement Information System (PROMIS) Assessment of Response to Treatment with Golimumab IV or Infliximab in Rheumatoid Arthritis Patients: Results from a Phase 4 Study
Clifton Bingham III¹, Shelly Kafka², Shawn Black², Stephen Xu³, Wayne Langholff⁴ and Jeffrey R Curtis⁵, ¹Johns Hopkins University, Baltimore, MD, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Research & Development, LLC, Spring House, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: AWARE (Comparative & Pragmatic Study of Golimumab [GLM] Intravenous [IV] vs Infliximab [IFX] in RA) is a Phase 4 study designed to provide a…
Abstract Number: 1982 • ACR Convergence 2020
Quality of Life of Patients with Facial Cutaneous Lupus Erythematosus
Josef Symon Concha¹, Daisy Yan¹, Christina Bax², Adarsh Ravishankar³, Robert Borucki⁴, Rui Feng⁴ and Victoria Werth⁵, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²University of Pennsylvania, Department of Dermatology, Philadelphia, ³University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ⁴University of Pennsylvania, Philadelphia, ⁵University of Pennsylvania and Corporal Michael J. Crescenz Veterans Administration Hospital, Philadelphia
Background/Purpose: Cutaneous Lupus Erythematosus (CLE) is an autoimmune skin disease that may occur with or without systemic lupus erythematosus (SLE). Active CLE lesions present with…
Abstract Number: 0570 • ACR Convergence 2020
The Patient Perspective on Using Digital Resources to Address Unmet Needs in Systemic Lupus Erythematosus
Jennifer Ra¹, Jerik Leung², Elizabeth Baker² and Alfred Kim¹, ¹Washington University School of Medicine, St. Louis, MO, ²Saint Louis University, College for Public Health and Social Justice, St. Louis
Background/Purpose: The clinical variability of systemic lupus erythematosus (SLE) caused by the unpredictability of flares contributes to patients experiencing a diminished sense of social support.…
Abstract Number: 1216 • ACR Convergence 2020
Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, and Health Related Quality of Life, and Reduced Fatigue over Time in Patients with Rheumatoid Arthritis Who Are Methotrexate-Naïve: Results from a Phase 3 Study
Rieke Alten¹, William F. C. Rigby², Alena Pechonkina³, Zhaoyu Yin⁴, Ken Hasegawa⁴, Thijs Hendrikx⁵, Tatsuya Atsumi⁶ and Rene Westhovens⁷, ¹Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Gilead Sciences, Inc., Foster City, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos BV, Leiden, Netherlands, ⁶Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan, ⁷University Hospitals Leuven, Belgium, Leuven, Belgium
Background/Purpose: In FINCH 3, filgotinib (FIL)—a potent, selective, oral JAK1 inhibitor1—in combination with methotrexate (MTX), demonstrated significant improvements in signs and symptoms of rheumatoid arthritis…
Abstract Number: 1984 • ACR Convergence 2020
Causal Pathways to Health-Related Quality of Life in Children with Juvenile Idiopathic Arthritis: Results from the ReACCh-Out Cohort
Kiem Oen¹, Jiahao Tian², Thomas Loughin², Roberta Berard³, Mercedes Chan⁴, Ciaran Duffy⁵, Brian Feldman⁶, Adam Huber⁷, Deborah Levy⁸, Dax G. Rumsey⁹, Natalie Shiff¹⁰, Shirley Tse¹¹, Lori Tucker⁴, Karen Watanabe-Duffy⁵ and Jaime Guzman¹², ¹University of Manitoba, Toronto, ON, Canada, ²Simon Fraser University, Burnaby, BC, Canada, ³London Health Sciences Centre, London, ON, Canada, ⁴BC Children's Hospital, Vancouver, BC, Canada, ⁵Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷Dalhousie University, Halifax, NS, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰Florida, Gainesville, FL, ¹¹SickKids, Toronto, ON, Canada, ¹²University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: The relative roles of disease activity and disability as determinants of health-related quality of life (HRQoL) in children with JIA have been controversial; sometimes…
Abstract Number: 0061 • ACR Convergence 2020
Rheumatologists’ Attitudes Toward Palliative Care and Medical Assistance in Dying
Alexandra Saltman¹, Caroline McGuinty², Gursimran Chandhoke³, Simon Oczkowski⁴, Heather McDonald-Blumer¹, Ebru Kaya⁵ and Kirsten Wentlandt⁶, ¹University Health Network and Sinai Health System, University of Toronto Faculty of Medicine, Toronto, ON, Canada, ²Ottawa Heart Institute and University of Ottawa, Ottawa, ON, Canada, ³Lakeridge Health, Oshawa, ON, Canada, ⁴Juravinski Hospital and McMaster University, Hamilton, ON, Canada, ⁵University Health Network,, University of Toronto Faculty of Medicine, Toronto, ON, Canada, ⁶University Health Network, University of Toronto Faculty of Medicine, Toronto, ON, Canada
Background/Purpose: Despite major advances in the treatment of systemic rheumatic diseases, a population remains—including those with systemic vasculitis, inflammatory myositis and systemic sclerosis—who suffer from…
Abstract Number: 0652 • ACR Convergence 2020
Changes in Serum Urate, in the First 6-months of Initiation or Change of Urate-Lowering Therapy, Associate with Immediate Health-Related Quality of Life Outcomes in People with Gout
Ruth Topless¹, Tony Merriman¹, Siamak Noorbaloochi² and Jasvinder Singh³, ¹University of Otago, Dunedin, New Zealand, ²University of Minnesota, Minneapolis, ³University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Few studies, if any, have found association of the biochemical cause of gout (high serum urate) with functional limitation and health-related quality of life…
Abstract Number: 1269 • ACR Convergence 2020
Evaluation of a Patient-reported Frailty Tool in Women with Systemic Lupus Erythematosus
Sarah Lieber¹, Stephen Paget¹, Jessica Berman¹, Medha Barbhaiya², Lisa Sammaritano², Kyriakos Kirou¹, John Carrino³, Musarrat Nahid⁴, Mangala Rajan⁴, Dina Sheira¹ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY, ³Hospital for Special Surgery, Hackensack, NJ, ⁴Weill Cornell Medicine, New York
Background/Purpose: Frailty has been associated with increased disability and mortality in SLE. To our knowledge, no patient-reported frailty tool has been evaluated alongside a standard…
Abstract Number: 2011 • ACR Convergence 2020
Olokizumab Improves Patient Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate: Results from the Double-Blind, Randomized Controlled Phase III Study
Evgeny Nasonov¹, Saeed Fatenejad², Mariana Ivanova³, Diana Krechikova⁴, Sofia Kuzkina⁵, Alexey Maslyanskiy⁶, Tatiana Plaksina⁷, Mikhail Samsonov⁵, Marina Stanislav¹, Tamara Tyabut⁸, Irina Vinogradova⁹, Sergey Yakushin¹⁰, Elena Zonova¹¹ and Mark Genovese¹², ¹FSBSI "Scientific Research Institute of Rheumatology n.a. V.A. Nasonova", Moscow, Russia, ²SFC Medica, LLC, Charlotte, NC, ³UMHAT St. Ivan Rilski, Clinic of Rheumatology, Sofia, Bulgaria, ⁴Non-governmental Healthcare Institution "Regional Clinical Hospital at Smolensk station of OJSC "Russian Railways"”, Smolensk, Russia, ⁵JSC “R-Pharm”, Moscow, Russia, ⁶SBHI "North-West Federal Medical Research Center n.a. V.A.Almazov", Saint Petersburg, Russia, ⁷SBHI of Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital n.a. P.A.Semashko", Nizhny Novgorod, Russia, ⁸Belarusian Medical Academy of Postgraduate Education, Minsk, Russia, ⁹Ulyanovsk Regional Clinical Hospital, Ulyanovsk, Russia, ¹⁰Ryazan State Medical University, Ryazan, Russia, ¹¹Novosibirsk State Medical University, State Clinical Polyclinic, Novosibirsk, Russia, ¹²Stanford University Medical Center, Palo Alto, CA
Background/Purpose: We previously reported positive efficacy and safety results of olokizumab (OKZ), an interleukin-6-inhibitor, in patients with RA inadequately controlled by MTX (NCT02760368; CREDO-1) [Nasonov…
Abstract Number: 0151 • ACR Convergence 2020
More Than Half of Newly Diagnosed RA Patients Are Not Convinced of the Necessity of RA Medicines: Associations with RA Characteristics, Symptoms, and Function in the Canadian Early Arthritis Cohort (CATCH)
Viviane Ta¹, Orit Schieir², Marie-France Valois³, Diane Tin⁴, Carol Hitchon⁵, Louis Bessette⁶, Carter Thorne⁴, Janet Pope⁷, Gilles Boire⁸, Edward Keystone⁹, Vivian Bykerk¹⁰, Susan Bartlett³ and Canadian Early Arthritis Cohort (CATCH) Investigators¹¹, ¹McGill University, Montreal, QC, Canada, ²Canadian Early Arthritis Cohort Study, Montreal, Canada, ³McGill University, Montreal, Canada, ⁴Southlake Regional Health Centre, Newmarket, ON, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Laval University, Quebec, Canada, ⁷Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ⁸Universite de Sherbrooke, Sherbrooke, Canada, ⁹The Rebecca MacDonald Centre for Arthritis, Mt. Sinai Hospital, Toronto, Canada, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: Although DMARDs are essential for early aggressive control of RA to reduce symptoms and disability, medication adherence is variable. Beliefs about the necessity of…
Abstract Number: 0725 • ACR Convergence 2020
A Data Science Evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) Questionnaire for Improving Management of JIA Patients
Humbert Quesada-Masachs¹, Michalis Faloutsos², Shomit Ghose³, Sara Marsal⁴, Consuelo Modesto⁴ and Estefania Quesada-Masachs⁵, ¹University of California Riverside, San Diego, ²University of California Riverside, Riverside, ³University of California Berkeley, San Francisco, ⁴Hospital Universitari Vall d'Hebron, Barcelona, Spain, ⁵Hospital Universitari Vall d'Hebron, San Diego
Background/Purpose: The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a questionnaire developed to comprehensively assess Juvenile Idiopathic Arthritis (JIA) patients. Despite being translated into 54…
Abstract Number: 1273 • ACR Convergence 2020
The Impact of the COVID-19 Pandemic on the Fibromyalgia Symptoms of SLE Patients
Rebecca Sadun¹, Jennifer Rogers², Kai Sun¹, Karissa Grier¹, Lisa Criscione-Schreiber³, Mithu Maheswaranathan¹, Jayanth Doss¹ and Megan Clowse⁴, ¹Duke University, Durham, NC, ²Duke, Durham, NC, ³Duke University School of Medicine, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: Many patients with SLE experience symptoms of chronic pain and fatigue, often meeting criteria for fibromyalgia (FM). In this study, we sought to examine…
Abstract Number: 0156 • ACR Convergence 2020
The Role of Biological Treatment in the Health-Related Quality of Life of Ankylosing Spondylitis Patients’ Assessment – Meta-Analysis
Wojciech Tański¹, Mariusz Chabowski², Natalia Świątoniowska-Lonc³ and Beata Jankowska-Polańska³, ¹4th Military Teaching Hospital, Wrocław, Poland, ²4th Military Teaching Hospital, Wroclaw Medical University, Wrocław, Poland, ³Wroclaw Medical University, Wrocław, Poland
Background/Purpose: Spondyloarthritis (SpA) is a chronic inflammatory rheumatic disease involving the axial skeleton, entheses and peripheral joints, and may occur together with extra-articular manifestations, such…
Abstract Number: 0877 • ACR Convergence 2020
Improvements in Global Functioning and Health-related Quality of Life and Their Association with Disease Activity and Functional Improvement in Patients with Active Ankylosing Spondylitis Treated with Upadacitinib
Uta Kiltz¹, Joachim Sieper², Atul Deodhar³, Patrick Zueger⁴, In-Ho Song⁴, Naijun Chen⁴ and Désirée van der Heijde⁵, ¹Rheumazentrum Ruhrgebiet, Herne, and Ruhr-University Bochum, Herne, Germany, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Oregon Health & Science University, Portland, OR, ⁴AbbVie Inc., North Chicago, IL, ⁵Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Upadacitinib (UPA) has been shown to be effective and well tolerated in patients with active ankylosing spondylitis (AS) [1]. However, improvements in global functioning…
Abstract Number: 1284 • ACR Convergence 2020
Application of a Novel Method for Determination of Muscle Mass Relative to Fat Mass in Women with Systemic Lupus Erythematosus and Association with Disability
Sarah Lieber¹, Patricia Katz², Joshua Baker³, Deanna Jannat-Khah⁴, Dina Sheira¹ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²University of California, San Francisco, Novato, CA, ³University of Pennsylvania, Philadelphia, PA, ⁴Hospital for Special Surgery, New York City, NY
Background/Purpose: Patients with SLE are at risk for both skeletal muscle loss and increased adiposity, which may predispose to worse health-related quality of life. Decreased…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].